Business
X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule
About this update from X4 Pharmaceuticals, Inc.
[{"type":"text","content":"BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that Christophe Arbet-Engels, MD, PhD, will be joining the company as its new Chief Medical Officer, bringing more than 25 years’ experience in strategic global drug development across a wide range of therapeutic areas including rare and orphan diseases. “We are thrilled to welcome Christophe to our leadership team at this exciting time at X4,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. “Christophe brings extensive experience in drug development, spanning research, clinical development, launch, and commercialization across global markets, which should further enable our growth as we near the submission of our first U.S. New Drug Application for mavorixafor in WHIM syndrome, prepare for our first potential U.S. commercial launch in 2024, and continue clinical development of mavorixafor in certain chronic neutropenic disorders. We would also like to thank Dr. Murray Stewart, who has been serving as our Interim Chief Medical Officer, for his exceptional contributions and his leadership. We look forward to his continued strategic guidance as an ongoing member of our Board of Directors.” Dr. Arbet-Engels also commented on his appointment: “I am honored to have been appointed to the role of CMO at X4 and excited to help advance the company’s mission to bring innovative therapies to patients with rare diseases of the immune system. The company has made great progress and I look forward to adding to its continued forward momentum. I believe mavorixafor has great potential to improve the lives of a significant number of patients given its oral profile and immune-modulating mechanism of action and I look forward to being an integral part of the team maximizing that opportunity for the benefit of patients in need across the world.” Dr. Arbet-Engels previously served as Chief Medical Officer at several life science companies, including Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, where he provided research and development leadership, advancing multiple candidates from pre-clinical through to late-stage clinical trials. Prior to these roles, he held a ...